Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent

Journal of Immunology

Volumn 181, Issue 8, 2008, Pages 5296-5305

  DeBenedette, Mark A ^a   Calderhead, David M ^a   Ketteringham, Helen ^a   Gamble, Alicia H ^a   Horvatinovich, Joe M ^a   Tcherepanova, Irina Y ^a   Nicolette, Charles A ^a   Healey, Don G ^a  

^a Argos Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD40 LIGAND; CD45RA ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MESSENGER RNA; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; CD45 ANTIGEN; IL2 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; RNA;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; ELECTROPORATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTOTOXICITY; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOTHERAPY; INFECTION; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTIGENS, CD28; ANTIGENS, CD45; ANTIGENS, NEOPLASM; CD40 LIGAND; CELL LINE, TUMOR; DENDRITIC CELLS; ELECTROPORATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INFECTION; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RNA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 54049140895     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.8.5296     Document Type: Article

References (52)

1. Lanzavecchia, A., and F. Sallusto. 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2: 982-987. (Pubitemid 37323221)
2. Appay, V., and S. L. Rowland-Jones. 2004. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin. Immunol. 16: 205-212. (Pubitemid 38569901)
3. + T-cell differentiation in response to viruses. Nat. Rev. Immunol. 3: 931-939.
4. + T lymphocytes. J. Immunol. 178: 4112-4119.
5. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
6. + and CD28 down-modulation on CD8 T cells during viral infection. Blood 96: 1021-1029.
7. Gamberg, J., I. Pardoe, M. I. Bowmer, C. Howley, and M. Grant. 2004. Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol. Cell Biol. 82: 38-46. (Pubitemid 38388718)
8. Zimmerli, S. C., A. Harari, C. Cellerai, F. Vallelian, P. A. Bart, and G. Pantaleo. 2005. HIV-1-specific IFN-γ/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102: 7239-7244.
9. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250.
10. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, N. Rufer, N. Lubenow, D. Speiser, J. C. Cerottini, P. Romero, and M. J. Pittet. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer. Res. 64: 2865-2873. (Pubitemid 38500627)
11. + memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198: 947-955.
12. + cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200: 1407-1417.
13. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102: 9571-9576.
14. Huang, J., H. T. Khong, M. E. Dudley, M. El-Gamil, Y. F. Li, S. A. Rosenberg, and P. F. Robbins. 2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28: 258-267. (Pubitemid 40593992)
15. Dudley, M. E., and S. A. Rosenberg. 2007. Adoptive cell transfer therapy. Semin. Oncol. 34: 524-531.
16. + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 13: 1857-1867.
17. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
18. Steinman, R. M., and H. Hemmi. 2006. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311: 17-58. (Pubitemid 47413194)
19. Lanzavecchia, A., and F. Sallusto. 2001. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 13: 291-298. (Pubitemid 32537700)
20. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
21. Steinman, R. M. 2003. The control of immunity and tolerance by dendritic cell. Pathol. Biol. 51: 59-60. (Pubitemid 36427570)
22. Lanzavecchia, A., and F. Sallusto. 2000. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290: 92-97. (Pubitemid 30752074)
23. Lanzavecchia, A., and F. Sallusto. 2005. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 17: 326-332. (Pubitemid 40692670)
24. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
25. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138-147. (Pubitemid 36287518)
26. Lu, W., L. C. Arraes, W. T. Ferreira, and J. M. Andrieu. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10: 1359-1365. (Pubitemid 40022718)
27. Garcia, F., M. Lejeune, N. Climent, C. Gil, J. Alcami, V. Morente, L. Alos, A. Ruiz, J. Setoain, E. Fumero, et al. 2005. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191: 1680-1685. (Pubitemid 40656756)
28. Gilboa, E., and J. Vieweg. 2004. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199: 251-263. (Pubitemid 38744521)
29. Mu, L. J., G. Gaudernack, S. Saeboe-Larssen, H. Hammerstad, A. Tierens, and G. Kvalheim. 2003. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand. J. Immunol. 58: 578-586.
30. Kalady, M. F., M. W. Onaitis, S. Emani, Z. Abdul-Wahab, S. K. Pruitt, and D. S. Tyler. 2004. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J. Gastrointest. Surg. 8: 175-181.
31. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M. A. Maurice, C. D. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109: 409-417. (Pubitemid 34141815)
32. Abdel-Wahab, Z., M. F. Kalady, S. Emani, M. W. Onaitis, O. I. Abdel-Wahab, R. Cisco, L. Wheless, T. Y. Cheng, D. S. Tyler, and S. K. Pruitt. 2003. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cell. Immunol. 224: 86-97. (Pubitemid 37345150)
33. Su, Z., J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63: 2127-2133. (Pubitemid 36538616)
34. Schaft, N., J. Dorrie, P. Thumann, V. E. Beck, I. Muller, E. S. Schultz, E. Kampgen, D. Dieckmann, and G. Schuler. 2005. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 174: 3087-3097. (Pubitemid 40279731)
35. Kalady, M. F., M. W. Onaitis, S. Emani, Z. Abdel-Wahab, D. S. Tyler, and S. K. Pruitt. 2004. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J. Surg. Res. 116: 24-31.
36. Calderhead, D. M., M. A. DeBenedette, H. Ketteringham, A. H. Gamble, J. M. Horvatinovich, I. Y. Tcherepanova, C. A. Nicolette, and D. G. Healey. 2008. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proin- flammatory CTL response. J. Immunother. 31: 731-744.
37. Bontkes, H. J., D. Kramer, J. J. Ruizendaal, E. W. Kueter, V. F. van Tendeloo, C. J. Meijer, and E. Hooijberg. 2007. Dendritic cells transfected with interleukin- 12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14: 366-375.
38. Tcherepanova, I., J. M. Adams, X. Feng, A. Hinohara, J. Horvatinovich, D. M. Calderhead, D. G. Healey, and C. A. Nicolette. 2008. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol. Biol. In press.
39. + T cells from a memory to memory/effector phenotype. J. Immunol. 168: 5538-5550.
40. + T cells differently expressing three cytolytic effector molecules. J. Immunol. 177: 4330-4340.
41. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101: 4260-4266.
42. Barbui, A. M., G. Borleri, E. Conti, A. Ciocca, A. Salvi, C. Mico, M. Introna, and A. Rambaldi. 2006. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. Exp. Hematol. 34: 475-485.
43. Betts, M. R., C. M. Gray, J. H. Cox, and G. Ferrari. 2006. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev. Vaccines 5: 505-516.
44. + T subsets with distinct replicative history and partial effector functions. Blood 102: 1779-1787.
45. + T cell differentiation in viral infection: a cell for all seasons. World J. Gastroenterol. 13: 4848-4857.
46. Dudley, M. E., and S. A. Rosenberg. 2007. Adoptive cell transfer therapy. Semin. Oncol. 34: 524-531.
47. 2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl. 4): A8-A22.
48. Bontkes, H. J., J. J. Ruizendaal, D. Kramer, C. J. Meijer, M. W. Schreurs, and E. Hooijberg. 2005. Interleukin-12 increases proliferation and interferon-γ production but not cytolytic activity of human antigen-specific effector memory cytotoxic T lymphocytes: power of the effect depends on the functional avidity of the T cell and the antigen concentration. Hum. Immunol. 66: 1137-1145.
49. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758. (Pubitemid 28110836)
50. + T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol. Immunother. 56: 1979-1991.
51. + T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J. Immunol. 180: 1526-1534.
52. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Devevre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854.